Tempest Therapeutics Selects Cincinnati Children's as Lead Partner for TPST-2003
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 11 2026
0mins
Tempest Therapeutics announced the selection of Cincinnati Children's Applied Gene and Cell Therapy Center as the lead contract development and manufacturing partner to conduct the formal technology transfer of TPST-2003, Tempest's dual-targeting CD19/BCMA CAR-T therapy under development for the treatment of relapsed/refractory multiple myeloma. Tempest recently announced that, as of a January 31, 2026 data cutoff, a total of 36 patients with rrMM had received one infusion of TPST-2003, including 24 patients in a prior Phase 1/2 investigator-initiated trial and 12 patients in the ongoing REDEEM-1 trial, representing one of the largest datasets evaluating a CD19/BCMA dual-targeting CAR-T therapy. As of the data cutoff, all six efficacy evaluable patients enrolled in the REDEEM-1 trial had achieved a complete response according to the International Myeloma Working Group uniform response criteria. Among 25 evaluable patients with measurable disease at baseline across both studies, the overall response rate was 100%. Tempest plans to present the results of the REDEEM-1 trial and updated results from the IIT at a scientific meeting later this year.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TPST?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TPST
About TPST
Tempest Therapeutics, Inc. is a clinical-stage biotechnology company moving towards late-stage development with a portfolio of targeted and immune-mediated product candidates with the potential to be first-in-class to treat a range of cancers. Its programs range from early research to the lead program, amezalpat, a pivotal study in first-line hepatocellular carcinoma (HCC). Its second clinical program, TPST-1495, is a novel, small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 (PGE2), a pathway implicated in multiple cancers. Its development strategy for TPST-1495 includes evaluation in familial adenomatous polyposis (FAP), a rare genetic disorder that increases the risk of gastrointestinal cancers. Its pipeline also includes TPST-2003, TPST-2206, TPST-3003, and TPST-3206. TPST-2003 is a new dual-targeting CD19/BCMA CAR-T asset. TPST-2206 is a dual-targeting CD70/CD70 CAR-T for renal cell carcinoma. TPST-3206 is an allogeneic dual-targeting CD70/CD70.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Tempest Therapeutics Appoints New Independent Directors
- New Board Members: Tempest Therapeutics appointed Drake Richey and John Yee as independent directors on June 4, 2026, bringing decades of experience in corporate finance and therapeutic product development to the Board, which will enhance strategic guidance.
- Cancer Treatment Vision: CEO Matt Angel stated that the addition of the new directors could further enable Tempest's vision in CAR-T cell therapy, aiming to provide effective treatment options for patients who have failed or relapsed from previous therapies.
- Rich Professional Background: Drake Richey, previously President of Bush & Company, has extensive experience in investment strategy and risk management, while John Yee, Senior Vice President at Apnimed, has held senior medical affairs roles at several prominent pharmaceutical companies, providing a strong medical background.
- Long-Term Success Strategy: The appointment of the new directors not only strengthens Tempest's leadership team but also supports the company's growth and capital allocation strategy, positioning it for long-term success in the competitive biotechnology market.
See More
Tempest Therapeutics Reports Q1 Losses and Cash Decline
- Financial Performance Decline: Tempest Therapeutics reported a Q1 GAAP EPS of -$2.53, an improvement from -$3.16 year-over-year, yet the net loss of $27.7 million indicates ongoing challenges in profitability.
- Cash Flow Strain: The company ended the quarter with only $1.8 million in cash and cash equivalents, a significant drop from $7.7 million on December 31, 2025, primarily due to one-time transaction costs associated with the asset acquisition, highlighting pressure on financial management.
- Financing Activities: Tempest Therapeutics is seeking up to $6 million in private placement to bolster liquidity, a move aimed at alleviating cash flow constraints and supporting future operational needs.
- Market Reaction: Despite showing signs of reduced losses in its financial report, investor concerns regarding ongoing cash flow issues may negatively impact stock prices, reflecting a cautious market sentiment towards the company's future prospects.
See More
Tempest Therapeutics Reports FY Losses
- Disappointing Earnings: Tempest Therapeutics reported a FY GAAP EPS of -$6.33, missing expectations by $0.23, indicating ongoing challenges in profitability that may undermine investor confidence.
- Deteriorating Cash Position: As of December 31, 2024, Tempest's cash and cash equivalents dropped to $7.7 million from $30.3 million a year earlier, highlighting pressures in cash management and operational expenditures that could limit future R&D investments.
- Funding Initiative Launched: Tempest Therapeutics announced a private placement of up to $6 million aimed at improving liquidity and supporting R&D projects, although market confidence in its fundraising ability may be affected by the disappointing earnings report.
- Cautious Market Reaction: Following the earnings miss, the market is adopting a cautious stance towards Tempest's future prospects, leading investors to potentially reassess their strategies and resulting in increased stock price volatility.
See More
Insider Purchases of RPC and TPST Stocks
- RPC Insider Purchase: Ridgepost Capital Director David M. McCoy purchased 70,000 shares of RPC at $7.37 each on Monday, totaling an investment of $515,900, reflecting confidence in the company's future and contributing to a 3.1% increase in RPC's stock price on Thursday.
- TPST Stock Acquisition: Tempest Therapeutics CEO Matthew Angel bought 231,482 shares at $2.16 each on Tuesday, amounting to $500,001, despite the stock declining by 4.6% on Thursday, indicating executive recognition of the company's value.
- Market Reaction Analysis: Although Angel's purchase price exceeds the current market price of $1.65, which is 23.8% lower than his purchase price, investors can still enter at a lower price, reflecting differing views on TPST's short-term volatility versus long-term potential.
- Executive Confidence Indicator: Insider buying is often seen as a positive signal for a company's future performance, especially amid market fluctuations, prompting investors to pay attention to these signals for potential investment opportunities.
See More
Tempest Therapeutics Secures $6 Million Private Placement Financing
- Financing Agreement Details: Tempest Therapeutics announced a securities purchase agreement for a private placement of up to $6 million with participation from new and existing institutional investors, expected to close around March 23, 2026, with proceeds aimed at supporting clinical development and operational needs.
- Stock Issuance Terms: Under the agreement, Tempest will issue 925,927 shares of common stock along with Series A and short-term Series B warrants, priced at $2.16 per share, reflecting the company's current market conditions and investor interest.
- Clinical Program Progress: Tempest is advancing a portfolio of small-molecule and CAR-T candidates, with Amezalpat currently in a Phase 2 trial for hepatocellular carcinoma, indicating the company's commitment to addressing difficult-to-treat cancers.
- Stock Performance Volatility: Despite a 19.65% drop in TPST's stock price to $1.84 at Monday's close, the stock rebounded slightly to $1.88 in after-hours trading, suggesting mixed market reactions to the financing news.
See More
Tempest Therapeutics Announces Private Placement of Common Stock and Warrants
- Financing Size: Tempest Therapeutics announced a private placement involving 925,927 shares of common stock and corresponding Series A and short-term Series B warrants, with expected gross proceeds of approximately $2 million, indicating the company's active engagement in capital markets.
- Warrant Details: Both Series A and short-term Series B warrants have an exercise price of $2.16 per share and are expected to become exercisable upon shareholder approval, potentially generating an additional $4 million in proceeds if fully exercised, enhancing the company's financial flexibility.
- Use of Proceeds: The company intends to utilize the net proceeds from this offering for working capital and other general corporate purposes, demonstrating its focus on future business development and efficient capital utilization.
- Market Reaction: Following the financing announcement, Tempest Therapeutics' stock price fell 11.79% in pre-market trading to $2.02, reflecting a cautious market sentiment regarding the financing, which may impact investor confidence.
See More
Tempest Therapeutics Appoints New Independent Directors
- New Board Members: Tempest Therapeutics appointed Drake Richey and John Yee as independent directors on June 4, 2026, bringing decades of experience in corporate finance and therapeutic product development to the Board, which will enhance strategic guidance.
- Cancer Treatment Vision: CEO Matt Angel stated that the addition of the new directors could further enable Tempest's vision in CAR-T cell therapy, aiming to provide effective treatment options for patients who have failed or relapsed from previous therapies.
- Rich Professional Background: Drake Richey, previously President of Bush & Company, has extensive experience in investment strategy and risk management, while John Yee, Senior Vice President at Apnimed, has held senior medical affairs roles at several prominent pharmaceutical companies, providing a strong medical background.
- Long-Term Success Strategy: The appointment of the new directors not only strengthens Tempest's leadership team but also supports the company's growth and capital allocation strategy, positioning it for long-term success in the competitive biotechnology market.
See More
Tempest Therapeutics Reports Q1 Losses and Cash Decline
- Financial Performance Decline: Tempest Therapeutics reported a Q1 GAAP EPS of -$2.53, an improvement from -$3.16 year-over-year, yet the net loss of $27.7 million indicates ongoing challenges in profitability.
- Cash Flow Strain: The company ended the quarter with only $1.8 million in cash and cash equivalents, a significant drop from $7.7 million on December 31, 2025, primarily due to one-time transaction costs associated with the asset acquisition, highlighting pressure on financial management.
- Financing Activities: Tempest Therapeutics is seeking up to $6 million in private placement to bolster liquidity, a move aimed at alleviating cash flow constraints and supporting future operational needs.
- Market Reaction: Despite showing signs of reduced losses in its financial report, investor concerns regarding ongoing cash flow issues may negatively impact stock prices, reflecting a cautious market sentiment towards the company's future prospects.
See More
Tempest Therapeutics Reports FY Losses
- Disappointing Earnings: Tempest Therapeutics reported a FY GAAP EPS of -$6.33, missing expectations by $0.23, indicating ongoing challenges in profitability that may undermine investor confidence.
- Deteriorating Cash Position: As of December 31, 2024, Tempest's cash and cash equivalents dropped to $7.7 million from $30.3 million a year earlier, highlighting pressures in cash management and operational expenditures that could limit future R&D investments.
- Funding Initiative Launched: Tempest Therapeutics announced a private placement of up to $6 million aimed at improving liquidity and supporting R&D projects, although market confidence in its fundraising ability may be affected by the disappointing earnings report.
- Cautious Market Reaction: Following the earnings miss, the market is adopting a cautious stance towards Tempest's future prospects, leading investors to potentially reassess their strategies and resulting in increased stock price volatility.
See More
Insider Purchases of RPC and TPST Stocks
- RPC Insider Purchase: Ridgepost Capital Director David M. McCoy purchased 70,000 shares of RPC at $7.37 each on Monday, totaling an investment of $515,900, reflecting confidence in the company's future and contributing to a 3.1% increase in RPC's stock price on Thursday.
- TPST Stock Acquisition: Tempest Therapeutics CEO Matthew Angel bought 231,482 shares at $2.16 each on Tuesday, amounting to $500,001, despite the stock declining by 4.6% on Thursday, indicating executive recognition of the company's value.
- Market Reaction Analysis: Although Angel's purchase price exceeds the current market price of $1.65, which is 23.8% lower than his purchase price, investors can still enter at a lower price, reflecting differing views on TPST's short-term volatility versus long-term potential.
- Executive Confidence Indicator: Insider buying is often seen as a positive signal for a company's future performance, especially amid market fluctuations, prompting investors to pay attention to these signals for potential investment opportunities.
See More
Tempest Therapeutics Secures $6 Million Private Placement Financing
- Financing Agreement Details: Tempest Therapeutics announced a securities purchase agreement for a private placement of up to $6 million with participation from new and existing institutional investors, expected to close around March 23, 2026, with proceeds aimed at supporting clinical development and operational needs.
- Stock Issuance Terms: Under the agreement, Tempest will issue 925,927 shares of common stock along with Series A and short-term Series B warrants, priced at $2.16 per share, reflecting the company's current market conditions and investor interest.
- Clinical Program Progress: Tempest is advancing a portfolio of small-molecule and CAR-T candidates, with Amezalpat currently in a Phase 2 trial for hepatocellular carcinoma, indicating the company's commitment to addressing difficult-to-treat cancers.
- Stock Performance Volatility: Despite a 19.65% drop in TPST's stock price to $1.84 at Monday's close, the stock rebounded slightly to $1.88 in after-hours trading, suggesting mixed market reactions to the financing news.
See More
Tempest Therapeutics Announces Private Placement of Common Stock and Warrants
- Financing Size: Tempest Therapeutics announced a private placement involving 925,927 shares of common stock and corresponding Series A and short-term Series B warrants, with expected gross proceeds of approximately $2 million, indicating the company's active engagement in capital markets.
- Warrant Details: Both Series A and short-term Series B warrants have an exercise price of $2.16 per share and are expected to become exercisable upon shareholder approval, potentially generating an additional $4 million in proceeds if fully exercised, enhancing the company's financial flexibility.
- Use of Proceeds: The company intends to utilize the net proceeds from this offering for working capital and other general corporate purposes, demonstrating its focus on future business development and efficient capital utilization.
- Market Reaction: Following the financing announcement, Tempest Therapeutics' stock price fell 11.79% in pre-market trading to $2.02, reflecting a cautious market sentiment regarding the financing, which may impact investor confidence.
See More
